Paperonium

Arthritis care · Ann Rheum Dis · 2021

Printed range starts at 8.5, a clear gain; rebuilt, it starts at about −1.3, below zero.

Its results sectiona clear gainIts own numbers, rebuiltcould be no benefit8.513.9−1.323.70 per 100510152025no benefit
Its results sectiona clear gainIts ownnumbers, rebuiltcould be no benefit8.513.9−1.323.7−100102030no benefitper 100

Extra patients per 100 who improved with goal-driven care

The paper says

Of 160 patients with spinal arthritis, 47.3% on goal-driven care (treatment adjusted to hit a set goal) improved 30% or more on a daily-life health score, against 36.1% on usual care: 11.2 more per 100. Its range puts the real benefit between 8.5 and 13.9.

Its own data show

A range that tight would need about 2,500 per group; the trial had 80. The same sentence says the gap could be luck: if the care did nothing, luck would give a gap this big about 1 time in 13. That fits a benefit from −1.3 to 23.7, nearly five times as wide, including zero.

A range spans the real benefits the data can’t rule out. It excludes zero (no benefit) only if luck would give the gap under 1 time in 20; at 1 in 13, it must include zero. The paper’s conclusion, no clear benefit, stands, but anyone copying its only range for this result records a clear gain the trial never showed.

“The summary” means the paper’s abstract: the short summary printed at its top, which is the part most readers see.

Read the paper →Full technical write-up →

Efficacy of a tight-control and treat-to-target strategy in axial spondyloarthritis: results of the open-label, pragmatic, cluster-randomised TICOSPA trial · Ann Rheum Dis (2021) · doi:10.1136/annrheumdis-2020-219585